Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateTimeSourceHeadlineSymbolCompany
03/06/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
03/06/202420:00PR Newswire (US)IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant StudyNASDAQ:IDYAIDEAYA Biosciences Inc
01/06/202406:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
01/06/202406:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
01/06/202406:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
31/05/202420:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
30/05/202407:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
29/05/202420:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
28/05/202420:00PR Newswire (US)IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentNASDAQ:IDYAIDEAYA Biosciences Inc
24/05/202411:21PR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
24/05/202407:05PR Newswire (US)IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
07/05/202420:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
07/05/202420:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
01/05/202420:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
26/04/202420:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
25/04/202400:05PR Newswire (US)IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyNASDAQ:IDYAIDEAYA Biosciences Inc
22/04/202420:00PR Newswire (US)IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerNASDAQ:IDYAIDEAYA Biosciences Inc
05/04/202421:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
01/04/202421:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
12/03/202421:00PR Newswire (US)IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
05/03/202409:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
05/03/202409:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
05/03/202409:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
04/03/202422:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
21/02/202408:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202422:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
14/02/202422:44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IDYAIDEAYA Biosciences Inc
14/02/202411:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IDYAIDEAYA Biosciences Inc
14/02/202408:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA